EcoDrugPlus

Integrin Beta 3a

Ensembl ID : ENSDARG00000056767
Gene Symbol: ITGB3A
5 Cross references
203 Possible Orthologues:

Integrin Beta 3b

Ensembl ID : ENSDARG00000045070
Gene Symbol: ITGB3B
27 Enzyme and pathways 5 Cross references
195 Possible Orthologues:

Integrin Subunit Beta 1

Ensembl ID : ENSDARG00000109929
Gene Symbol: ITGB1
3 Cross references
220 Possible Orthologues:

Integrin, Alpha 2b

Ensembl ID : ENSDARG00000018687
Gene Symbol: ITGA2B
20 Enzyme and pathways 5 Cross references
191 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSDARG00000006353
Gene Symbol: ITGA5
6 Enzyme and pathways 5 Cross references
206 Possible Orthologues:

Integrin, Alpha V

Ensembl ID : ENSDARG00000006314
Gene Symbol: ITGAV
19 Enzyme and pathways 5 Cross references
238 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSDARG00000071863
Gene Symbol: ITGB1A
23 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Integrin, Beta 1b

Ensembl ID : ENSDARG00000104484
Gene Symbol: ITGB1B
5 Cross references
220 Possible Orthologues:

Integrin, Beta 1b.1

Ensembl ID : ENSDARG00000053232
Gene Symbol: ITGB1B.1
5 Cross references
215 Possible Orthologues:

Integrin, Beta 1b.2

Ensembl ID : ENSDARG00000022689
Gene Symbol: ITGB1B.2
5 Cross references
215 Possible Orthologues:

Integrin, Beta 5

Ensembl ID : ENSDARG00000012942
Gene Symbol: ITGB5
12 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Integrin, Beta 6

Ensembl ID : ENSDARG00000002494
Gene Symbol: ITGB6
5 Enzyme and pathways 5 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).